Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 28 11:53 ETSource: BioPharma Dive
From the source
Read at biopharmadive.comLilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.
